Research Articles - Retinitis Pigmentosa
Oregon Health & Science University (OHSU) is launching a three-year natural history study for people with X-linked retinoschisis (XLRS). Funded by the Foundation Fighting Blindness and Applied Genetic Technologies Corporation (AGTC), the investigation’s primary goal is to identify outcome measures — such as changes in vision or retinal structure — that could be useful in evaluating the effectiveness of
A highly potent synthetic form of THC, the substance in marijuana that produces a high for users, has shown strong vision-preserving effects in rats with a form of autosomal dominant retinitis pigmentosa (adRP). Rats with adRP that were injected with the synthetic THC known as HU210 had 40 percent more rows of photoreceptors and 70 percent greater retinal sensitivity than untreated rats. The treatment also protected the connections between photoreceptors and other
- ReNeuron, a stem cell development company in the United Kingdom, is planning to file for regulatory approval in late 2013 to launch a clinical trial of a stem cell treatment for people with retinitis pigmentosa. The company announced its plans on June 15, 2012, at the 10th Annual Meeting of the International Society for Stem Cell Research (ISSCR) in Yokohama, Japan.
A grandmother of 10 who was diagnosed with retinitis pigmentosa (RP) 25 years ago is one of the first two people to receive an implant of the Argus® II Retinal Prosthesis System since it became commercially available in the United States. She is hopeful that the device, when activated after she recovers from surgery and receives training, will enable her to travel more and see the movement and activity of her grandchildren.
A new gene linked to autosomal dominant retinitis pigmentosa (adRP) has been identified, thanks to a Foundation Fighting Blindness-funded genetic study that began with an Acadian family from Louisiana whose vision loss can be traced back to the early 1800s. Led by Stephen Daiger, Ph.D., at the University of Texas Health Science Center in Houston, an international research collaborative found that mutations in the gene HK1 cause
Just because a photoreceptor has stopped working due to the effects of a retinal degenerative disease doesn’t mean it’s forever lost. In fact, as the Foundation reported previously, José Sahel, M.D., a researcher at the Institut de la Vision in Paris, is developing a treatment to reactivate cones which have lost their light-sensing, antenna-like projections known as outer segments, but still retain their cell bodies, or inner segments.
At the Foundation’s meeting of Translational Research Acceleration Program (TRAP) investigators in Las Vegas earlier this week, Al Lewin, Ph.D., of the University of Florida, discussed progress in tackling the vexing problem of developing gene therapies for autosomal dominant retinal disease — specifically retinitis pigmentosa (RP) caused by mutations in the gene rhodopsin (RHO). His team’s project is funded through
A drug developed by the company QLT for the treatment of retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) caused by mutations in the genes RPE65 or LRAT restored visual acuity or visual field in 11 of 14 patients in a Phase 1B clinical trial. Vision improvements for a seven-day course of the drug were sustained for two years for some study participants. No serious adverse events
- Thanks to success in preclinical studies funded in part by the Foundation Fighting Blindness, the Irish biopharmaceutical company Genable Technologies has received a €5 million (equivalent to about $6.8 million) venture capital investment to advance its gene therapy for autosomal dominant retinitis pigmentosa (adRP) into a clinical trial.